NASDAQ:APTO - Aptose Biosciences Stock Price, Forecast & News

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, APTO stock has increased by 2.6% and is now trading at $5.99. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences.

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Aptose Biosciences.

Aptose Biosciences Inc. (NASDAQ:APTO) issued its quarterly earnings results on Tuesday, March, 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.01. View Aptose Biosciences' earnings history.

5 analysts have issued 12 month price objectives for Aptose Biosciences' shares. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price. View analysts' price targets for Aptose Biosciences.

News stories about APTO stock have been trending somewhat negative on Saturday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aptose Biosciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAptose Biosciences.

Aptose Biosciences saw a decline in short interest in March. As of March 13th, there was short interest totaling 367,400 shares, a decline of 5.7% from the February 27th total of 389,800 shares. Based on an average trading volume of 924,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.5% of the shares of the company are sold short. View Aptose Biosciences' Current Options Chain.

Some companies that are related to Aptose Biosciences include Fate Therapeutics (FATE), Bill.com (RVMD), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Regenxbio (RGNX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), I-Mab (BDTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), Beam Therapeutics (BEAM), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), Oyster Point Pharma (OYST) and Krystal Biotech (KRYS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), AT&T (T), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY) and Micron Technology (MU).

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (1.33%), Driehaus Capital Management LLC (1.28%), Point72 Asset Management L.P. (1.01%), P.A.W. Capital Corp (0.89%), Schonfeld Strategic Advisors LLC (0.84%) and Voss Capital LLC (0.40%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View institutional ownership trends for Aptose Biosciences.

APTO stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc, and Sanders Morris Harris LLC. View insider buying and selling activity for Aptose Biosciences.

APTO stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Driehaus Capital Management LLC, Schonfeld Strategic Advisors LLC, Voss Capital LLC, P.A.W. Capital Corp, Monashee Investment Management LLC, Renaissance Technologies LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice. View insider buying and selling activity for Aptose Biosciences.

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTO stock can currently be purchased for approximately $5.99.

Aptose Biosciences has a market capitalization of $456.86 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.  View additional information about Aptose Biosciences.

The official website for Aptose Biosciences is http://www.aptose.com/.

Aptose Biosciences' mailing address is 12770 HIGH BLUFF DRIVE SUITE 120, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected]